Core Insights - Wall Street analysts expect Insulet (PODD) to report quarterly earnings of $1.05 per share, reflecting a year-over-year decline of 25% [1] - Revenue is anticipated to be $581.65 million, which represents a 14.1% increase from the same quarter last year [1] - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analysts' assessments [1] Revenue Estimates - Analysts forecast 'Revenue- Total Omnipod' to reach $575.12 million, indicating a year-over-year change of +14.8% [4] - The estimated 'Revenue- Drug Delivery' is projected at $6.07 million, reflecting a decline of 31% from the previous year [4] - 'Revenue- International Omnipod' is expected to be $140.18 million, showing a year-over-year increase of +31.8% [4] - 'Revenue- U.S. Omnipod' is likely to reach $434.94 million, indicating a change of +10.2% from the prior-year quarter [5] Stock Performance - Over the past month, Insulet shares have recorded returns of +3.4%, compared to the Zacks S&P 500 composite's +4.9% change [5] - Insulet holds a Zacks Rank 3 (Hold), suggesting that its performance is expected to align with the overall market in the upcoming period [5]

Core Viewpoint - Insulet Corporation is positioned for growth due to its rapid commercial expansion, increasing market access for the Omnipod platform, and the rising adoption of Omnipod 5, despite facing macroeconomic challenges [1][2]. Financial Performance - Insulet's stock has increased by 44.2% over the past year, outperforming the industry growth of 17.8% and the S&P 500's gain of 24.2% [2]. - The company has a market capitalization of $19.67 billion and has exceeded earnings estimates in three of the last four quarters, with an average surprise of 52.38% [2]. Market Expansion and Product Focus - Insulet is strategically expanding its global presence, transitioning from Omnipod GO to Omnipod 5, which is gaining strong customer adoption across various market segments [3][5]. - In 2024, Omnipod 5 was launched in the UK, Germany, France, and the Netherlands, with plans for further international expansion through integration with FreeStyle Libre 2 Plus and G7 [4]. Customer Growth and Strategy - The strategy of moving patients from multiple daily injections to Omnipod therapy is significantly increasing the customer base, with sequential and year-over-year growth noted in the third quarter [5]. - Insulet is investing in commercial expansion by gradually increasing its salesforce and entering targeted pediatric centers [5]. Product Innovation - Omnipod 5 is highlighted as the only FDA-cleared, fully disposable pod-based automated insulin delivery system, with attributes such as wearability and ease of use driving its rapid market adoption [6]. Revenue Growth Potential - Insulet is approaching $0.5 billion in international revenues for 2024, with growth rates exceeding 20%, indicating substantial potential for continued global expansion [7]. Financial Stability - As of the third quarter of 2024, Insulet had cash and cash equivalents of $903 million and current debt of $42 million, reflecting strong financial stability [8]. - The debt-to-capital ratio improved to 55.6X, and times interest earned increased to 8.3X, indicating enhanced solvency [10]. Cost Challenges - Insulet faces rising production costs for Omnipod 5, supply chain disruptions, and labor shortages, which are pressuring profit margins [11]. - Selling, general, and administrative expenses rose by 29.6% year-over-year due to increased headcount and organizational restructuring [11].

Company Developments - Insulet made its Omnipod 5 AID system compatible with Abbott's FreeStyle Libre 2 Plus CGM sensor in the United States in November 2024 [1] - The company released the Omnipod 5 App for iPhone in the United States in October 2024, featuring a Custom Foods feature for carbohydrate tracking [1] - Insulet expanded the commercial availability of Omnipod 5 to five more countries: Italy, Denmark, Finland, Norway, and Sweden, with compatibility for both Abbott's FreeStyle Libre 2 Plus and Dexcom G6 CGM sensors [5] - Omnipod 5 is recognized as the number one insulin pump for new users in Europe and the top prescribed AID system in the United States [7] - Omnipod 5 is the first tubeless AID system for individuals aged two years and older with type 1 diabetes, simplifying diabetes management with SmartAdjust technology [9] - Omnipod 5 demonstrated strong clinical results in the United States since its 2022 launch and expanded to the UK, Germany, France, and the Netherlands by June 2024 [10] Stock Performance and Market Sentiment - PODD shares rose 0.7% to $270 in after-market trading following the announcement on Jan 14 [2] - Insulet's shares have risen 33.7% in the past year, outperforming the industry's 7.8% growth [4] - The company has a market capitalization of $18.80 billion and is expected to see a 17.1% earnings increase in 2024 with a 21.2% revenue improvement [6] - Insulet delivered an average earnings beat of 52.4% over the trailing four quarters [6] Industry Prospects - The global diabetes devices market was valued at $30.31 billion in 2023 and is expected to grow at a CAGR of 7.5% through 2030 [3] - Market growth is driven by increasing diabetes prevalence, rising usage of insulin-delivery devices, and high obesity rates [3] - The industry is characterized by high innovation, focusing on accurate and efficient diagnosis and treatment solutions [3] Competitor Performance - Omnicell (OMCL) has an estimated earnings growth rate of 72.7% for Q4 2024 and delivered an average earnings surprise of 121.74% over the trailing four quarters [8] - Veracyte (VCYT) delivered an average earnings surprise of 520.58% over the trailing four quarters, with shares rising 49.2% in the past year [11] - ResMed (RMD) has an estimated growth rate of 21.1% for 2025 and delivered an average earnings surprise of 6.41% over the trailing four quarters [11]

EnglishItalianoEspañolPortuguêsDeutschالعربيةFrançaisImportant DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your ...

Insulet Corp. (PODD) announced that its Omnipod 5 Automated Insulin Delivery (“AID”) System is now compatible with Abbott’s (ABT) FreeStyle Libre 2 Plus continuous glucose monitoring (CGM) sensor in the United States. The latest development represents a significant step forward in the company’s efforts to expand access to its innovative, tubeless Omnipod 5 AID System for more people.In August 2024, the FDA cleared Omnipod 5 for use by people with type 2 diabetes (18 years and above), expanding the technolog ...

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.I last covered the insulin pump maker Insulet (NASDAQ: PODD ) in a note for Seeking Alpha back in June, noting the company's stock price had recovered from a devastating be ...

Insulet Corporation (PODD) reported third-quarter 2024 adjusted earnings per share (EPS) of 90 cents, up significantly 26.8% from the year-ago period’s figure. The bottom line surpassed the Zacks Consensus Estimate by 16.9%.GAAP EPS was $1.08, up 45.9% from the year-ago figure of 74 cents.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.Following the earnings announcement, PODD’s share price surged 2.9% to $275.7 yesterday.PODD’s Q3 RevenuesRevenues totaled $543.9 million, which beat t ...

Core Viewpoint - Insulet's stock surged nearly 10% following a strong Q3 performance, with sales of $544 million and adjusted earnings of $0.90 per share, exceeding consensus estimates [1][2]. Financial Performance - Insulet reported a revenue of $544 million, reflecting a 26% year-over-year growth, with U.S. and International Omnipod sales growing by 23% and 36%, respectively [2]. - The adjusted EBITDA margin increased by 410 basis points year-over-year to 23.2% in Q3, contributing to an adjusted earnings per share of $0.90, up from $0.71 in the prior-year quarter [2]. Future Outlook - The company anticipates sales growth of 20% to 21% in 2024, an increase from the previous outlook of 16% to 19% [2]. Stock Performance - Insulet's stock (PODD) has gained 23%, performing in line with the S&P 500 index, which is up 25% [3]. - The stock's performance has been volatile over the past three years, with returns of 4% in 2021, 11% in 2022, and -26% in 2023 [3]. Valuation Perspective - The stock is currently priced around $270, trading at 11 times trailing revenues, compared to an average price-to-sales ratio of 14 times over the last three years [4]. - The decline in valuation appears justified due to potential long-term impacts from new GLP-1 drugs on Insulet's sales, which may reduce demand for insulin pumps [4].

Financial Data and Key Metrics Changes - Insulet Corporation achieved a record total revenue of over $2 billion for the first time in its history, with Q3 revenue growth of 25% year-over-year, driven by total Omnipod revenue growth of 26% [8][29] - U.S. Omnipod revenue grew by 23%, while international revenue grew by 35% [11][32] - Gross margin improved to 69.3%, up 150 basis points, primarily due to pricing benefits and improved manufacturing efficiencies [34][35] Business Line Data and Key Metrics Changes - Total Omnipod revenue growth was 26%, with U.S. growth at 23% and international growth at 35% [11][32] - Type 2 diabetes users represented over 25% of U.S. new customer starts in Q3, indicating strong adoption following the FDA clearance for the type 2 label expansion [14][15] - Drug Delivery revenue was $10 million, exceeding guidance due to increased orders from partners [34] Market Data and Key Metrics Changes - Omnipod is now the 1 insulin pump for new pump users in Europe, reflecting strong market penetration [9][24] - International markets showed stable sequential new customer starts, with significant growth in the U.K. and Germany, and early traction in France and the Netherlands [9][32] - The company expects to reach over 40% of the 2.5 million type 2 insulin-intensive population in the U.S. by 2025 through expanded sales efforts [17][68] Company Strategy and Development Direction - The company is focused on expanding the Omnipod 5 platform, driving growth in both type 1 and type 2 diabetes markets, and accelerating international growth [10][12] - Insulet plans to expand its sales force and commercial relationships to capture the type 2 diabetes market, which is currently less than 5% penetrated [15][16] - The company aims to maintain its market leadership by leveraging its differentiated product offerings and expanding its manufacturing capabilities [26][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving sequential and year-over-year growth in new customer starts for both U.S. and international markets in Q4 [10][11] - The type 2 label expansion is expected to significantly contribute to revenue growth starting in 2025, with a strong pipeline of new customer starts [31][40] - Management highlighted the importance of operational excellence and margin expansion as key drivers for long-term growth [35][42] Other Important Information - The company ended the quarter with approximately $900 million in cash and full access to a $300 million credit facility, indicating strong liquidity [37] - Insulet is on track to launch Omnipod 5 integrated with Abbott's FreeStyle Libre 2 Plus sensor by the end of the year, enhancing its product offerings [20][23] Q&A Session Summary Question: Insights on European Market Performance - Management confirmed that Omnipod 5 is the 1 pump in the markets served in Europe, with strong growth in new customer starts, particularly in the U.K. and Germany [46][51] Question: Type 2 Market Penetration Potential - Management believes that type 2 penetration can grow significantly, potentially doubling or tripling over the next few years, driven by the unique position of Omnipod 5 in the market [55] Question: Commercial Preparation for Type 2 - Management indicated that they are expanding their sales force to reach over 40% of type 2 insulin-intensive users and are targeting high-prescribing PCP practices [67][68] Question: Q4 Guidance and Seasonal Trends - Management acknowledged that the Q4 guidance reflects a normalized growth rate, considering previous stocking dynamics, and remains confident in achieving over 20% growth [71][72] Question: Initial Feedback from Type 2 Patients - Management reported positive initial feedback from type 2 patients, highlighting the simplicity and effectiveness of Omnipod 5 in managing diabetes [76][78] Question: Impact of CGM Integrations - Management noted that sensor integrations, particularly with G7 and Libre 2 Plus, have positively impacted new customer starts and overall growth [96][98]

Core Insights - Insulet reported $543.9 million in revenue for Q3 2024, a year-over-year increase of 25.7% and a surprise of +4.90% over the Zacks Consensus Estimate of $518.5 million [1] - The EPS for the same period was $0.90, compared to $0.71 a year ago, resulting in a surprise of +16.88% over the consensus estimate of $0.77 [1] Revenue Breakdown - International Omnipod revenue reached $138 million, exceeding the six-analyst average estimate of $123.11 million, with a year-over-year change of +36.1% [3] - U.S. Omnipod revenue was $395.60 million, surpassing the six-analyst average estimate of $391.62 million, reflecting a year-over-year change of +23.4% [3] - Total Omnipod revenue amounted to $533.60 million, exceeding the six-analyst average estimate of $514.73 million, with a year-over-year change of +26.5% [3] - Drug Delivery revenue was reported at $10.30 million, compared to the $3.28 million average estimate, showing a year-over-year change of -3.7% [3] Stock Performance - Insulet's shares have returned +3.2% over the past month, matching the Zacks S&P 500 composite's +3.2% change [4] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [4]